SCHEMBL140959

SCHEMBL140959

Nc1ccc(-c2ccc(N)c(N=C=O)c2N=C=O)cc1

nearest known ligand 0.34

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.34
TDP1 Q9NUW8 2/20 0.34
ALDH1A1 P00352 1/20 0.34
TP53 P04637 1/20 0.34
GABRA1 P14867 1/20 0.32
GABRB2 P47870 1/20 0.32
KIF11 P52732 1/20 0.31
TAAR1 Q96RJ0 1/20 0.30
HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4313276 0.80 GABRA1 (0.43) CYP3A4TDP1GABRA1GABRB2
SCHEMBL9408129 0.73 CYP3A4 (0.40) CYP3A4TDP1ALDH1A1TP53TAAR1
SCHEMBL10582680 0.71 ALDH1A1 (0.41) CYP3A4TDP1ALDH1A1
SCHEMBL29706645 0.69 CYP3A4 (0.41) CYP3A4TDP1ALDH1A1TP53GABRA1
SCHEMBL9408113 0.69 CYP3A4 (0.43) CYP3A4TDP1ALDH1A1TP53KIF11
SCHEMBL20108074 0.69 TDP1 (0.50) CYP3A4TDP1ALDH1A1TP53KIF11
SCHEMBL10798784 0.68 GABRA1 (0.42) CYP3A4GABRA1GABRB2
SCHEMBL2489722 0.68 CYP3A4 (0.37) CYP3A4TDP1ALDH1A1GABRA1GABRB2
SCHEMBL31534012 0.68 RPS6KA3 (0.41) CYP3A4TDP1ALDH1A1TP53TAAR1
SCHEMBL5373569 0.66 CYP3A4 (0.38) CYP3A4TDP1ALDH1A1GABRA1GABRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1239 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4720199-A1 SELF-CROSSLINKABLE URETHANE (METH)ACRYLATES ARKEMA France (FR) 2026-04-08 EP claimed
US-20260042878-A1 Curable Compositions Comprising At Least One Silane-Modified Polymer HENKEL AG & CO KGAA (DE) 2026-02-12 US claimed
US-12448476-B2 Multi(meth)acrylate-functionalized oligomers and methods of preparing and using such oligomers ARKEMA FRANCE (FR) 2025-10-21 US claimed
US-12343905-B2 Method for producing cycloolefin resin-decorative molded article RIMTEC CORPORATION (JP) 2025-07-01 US claimed
CN-114630852-B Poly (meth) acrylate functionalized oligomers and methods of making and using such oligomers 阿科玛法国公司 2025-02-11 CN claimed
CN-119119799-A Water-based PI matt oil 苏州市贝特利高分子材料股份有限公司 2024-12-13 CN claimed
WO-2024245621-A1 SELF-CROSSLINKABLE URETHANE (METH)ACRYLATES ARKEMA FRANCE (FR) 2024-12-05 WO claimed
US-12139447-B2 Method for diisocyanate recovery from distillation residues with bitumen COVESTRO DEUTSCHLAND AG (DE) 2024-11-12 US claimed
EP-4455178-A1 CURABLE COMPOSITIONS COMPRISING AT LEAST ONE SILANE-MODIFIED POLYMER Henkel AG & Co. KGaA (DE) 2024-10-30 EP claimed
EP-3738987-B1 RADIATION CURABLE POLYMERS HENKEL AG & CO KGAA (DE) 2024-07-10 EP claimed
EP-2097464-A1 POLYAMIDE POLYOLS AND POLYURETHANES, METHODS FOR MAKING AND USING, AND PRODUCTS MADE THEREFROM Arizona Chemical Company (US) 2009-09-09 EP claimed
US-20090053490-A1 Highly Filled Composite Materials CLAUSI ROBERT N 2009-02-26 US claimed
EP-1991608-A1 HIGHLY FILLED COMPOSITE MATERIALS Clausi, Robert N. (CA) 2008-11-19 EP claimed
US-20080223519-A1 POLYAMIDE POLYOLS AND POLYURETHANES, METHODS FOR MAKING AND USING, AND PRODUCTS MADE THEREFROM BANK OF AMERICA, N.A. 2008-09-18 US claimed
WO-2008070762-A1 POLYAMIDE POLYOLS AND POLYURETHANES, METHODS FOR MAKING AND USING, AND PRODUCTS MADE THEREFROM ARIZONA CHEMICAL COMPANY (US) 2008-06-12 WO claimed
WO-2007095730-A1 HIGHLY FILLED COMPOSITE MATERIALS CLAUSI ROBERT N (CA) 2007-08-30 WO claimed
US-6930196-B2 Polyurethane hydrogel contact lens NOVARTIS AG (CH) 2005-08-16 US claimed
US-6520186-B2 Polyurea, polyurethanes containing silicon compounds L'OREAL (FR) 2003-02-18 US claimed
US-20020147268-A1 Reshapable hair styling composition comprising silicon-containing polycondensates L'OREAL S.A. (FR) 2002-10-10 US claimed
US-20020072562-A1 Methods and compositions for coating a surface GEOCEL HOLDINGS CORPORATION 2002-06-13 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260042878-A1 Curable Compositions Comprising At Least One Silane-Modified Polymer CDH1, MECP2, COL14A1 CYP3A4 4292/4885TDP1 2140/4885ALDH1A1 2682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.